On August 12, 2026, the U.S. Food and Drug Administration (FDA) issued Warning Letter 320-26-112 to K.C. Pharmaceuticals, Inc., a pharmaceutical manufacturer located in Pomona, California. The warning letter identified significant violations of Current Good Manufacturing Practice (CGMP) regulations, raising concerns about sterile drug manufacturing, laboratory testing, quality control procedures, and patient safety. This is exactly why you need GL-Technologies, we are specialists in this industry and can prevent your organization from potential issues with the FDA.
The FDA's findings followed an inspection conducted between January 20 and February 13, 2026. Investigators identified deficiencies involving contamination prevention, inadequate manufacturing controls, incomplete stability testing, insufficient laboratory procedures, and weaknesses in the company's quality management system.
The agency determined that the company's manufacturing methods, facilities, or controls did not comply with CGMP requirements, making its drug products legally adulterated under the Federal Food, Drug, and Cosmetic Act. This regulatory classification does not necessarily establish that every product was contaminated, but it reflects serious deficiencies in manufacturing controls.
The warning letter serves as an important reminder to pharmaceutical manufacturers that regulatory compliance requires ongoing validation, reliable laboratory equipment, documented procedures, and effective quality assurance programs.
FDA
1. Sterile Drug Manufacturing and Contamination Control Failures
One of the most concerning findings involved failures in aseptic processing procedures designed to prevent microbiological contamination.
According to the FDA, K.C. Pharmaceuticals continued manufacturing and releasing sterile drug products following failed media fill tests in June, September, and November 2024.
Media fill testing is essential for validating aseptic manufacturing processes. These simulations use microbiological growth media to evaluate whether manufacturing operations can consistently prevent contamination.
When media fills fail, pharmaceutical manufacturers must investigate potential causes, evaluate affected products, and implement appropriate corrective and preventive actions (CAPA).
The FDA determined that the company's investigations were inadequate and that proposed root causes lacked sufficient supporting evidence.
The agency also identified concerns involving cleanroom practices, personnel interventions, and airflow controls.
These findings highlight why pharmaceutical manufacturers must prioritize:
-
- Aseptic process validation and media fill testing
- Cleanroom qualification and environmental monitoring
- Airflow visualization studies
- Employee training and contamination prevention
- Documented investigations and effective CAPA programs - Without these safeguards, manufacturers cannot reliably demonstrate that sterile products meet required quality standards.
- Aseptic process validation and media fill testing
2. Inadequate Visual Inspection and Particulate Detection
- Another significant violation involved the company's visual inspection procedures for sterile over-the-counter pharmaceutical products.
- The FDA found that K.C. Pharmaceuticals did not maintain an adequate inspection program to identify visible particulate matter and other defects.
Particulate contamination may originate from manufacturing equipment, packaging materials, environmental conditions, or production processes.
Depending on the product and its intended use, foreign particles can create significant quality and patient safety risks.
The company relied on testing procedures that did not adequately address all potential defects. The FDA specifically raised concerns about the absence of comprehensive visual inspection and appropriate particulate detection methods.
Effective pharmaceutical visual inspection programs should incorporate validated inspection techniques, qualified equipment, trained personnel, and documented acceptance criteria.
Manufacturers must also evaluate whether their inspection procedures remain effective as equipment, packaging, and manufacturing conditions change.
3. Pharmaceutical Laboratory Testing and Stability Program Deficiencies
The FDA also identified significant weaknesses in the company's pharmaceutical stability testing program.
Stability testing helps determine whether pharmaceutical products maintain their identity, strength, quality, and purity throughout their stated shelf life.
The agency found that K.C. Pharmaceuticals had not adequately established stability-indicating analytical methods for certain products.
For example, the warning letter discussed deficiencies involving testing methods for naphazoline hydrochloride, an active pharmaceutical ingredient.
Without appropriately validated stability-indicating methods, manufacturers may be unable to reliably detect changes in product potency or degradation over time.
The FDA also identified missing stability time points, incomplete testing, and incorrect testing procedures.
These findings demonstrate the importance of comprehensive pharmaceutical laboratory support, including analytical method validation, stability program management, equipment qualification, and accurate documentation.
Reliable stability testing is not simply a regulatory requirement. It is essential for establishing scientifically supported product expiration dates and maintaining consistent pharmaceutical quality.
4. Laboratory Equipment Qualification and System Suitability Problems
The warning letter identified additional deficiencies involving laboratory equipment and analytical testing procedures.
According to the FDA, the company routinely performed total organic carbon (TOC) and conductivity measurements without adequately conducting required system suitability testing before use.
System suitability testing helps verify that analytical equipment and methods are functioning appropriately before generating critical laboratory data.
When these checks are missing, manufacturers may lack sufficient assurance that testing results are reliable.
Pharmaceutical laboratories depend on properly maintained, qualified, and calibrated instruments to support product release decisions and regulatory compliance.
Important laboratory quality practices include routine equipment calibration, analytical method validation, instrument qualification, preventive maintenance, and documented system suitability testing.
These activities are especially important for pharmaceutical manufacturers operating under FDA regulations, where inaccurate laboratory results can affect product quality decisions.
5. Quality Control and Complaint Investigation Failures
The FDA identified weaknesses in the company's quality control unit, particularly its complaint handling and investigation procedures.
The agency found that complaint investigations were sometimes delayed or incomplete and that complaint severity was not consistently evaluated appropriately.
A pharmaceutical quality unit must have sufficient authority, resources, and independence to identify manufacturing problems and ensure corrective actions are implemented.
Effective complaint management requires manufacturers to document reported problems, evaluate potential patient safety risks, investigate root causes, and determine whether additional testing or product recalls are necessary.
The FDA also emphasized that K.C. Pharmaceuticals had received a previous warning letter in August 2023 involving similar CGMP violations.
The recurrence of these issues raised additional concerns about the effectiveness and sustainability of the company's corrective actions.
6. FDA Drug Recall and Manufacturing Suspension
The consequences of the manufacturing deficiencies extended beyond the inspection findings.
On February 18, 2026, K.C. Pharmaceuticals initiated a voluntary recall of commercial drug products manufactured between March 27 and November 7, 2024, because of failed media fills and insufficient sterility assurance.
The FDA also acknowledged the company's commitment to suspend production of the affected categories of over-the-counter drug products at the facility.
Before resuming regulated drug manufacturing operations, the company was instructed to notify the FDA and provide information demonstrating that identified deficiencies had been addressed.
The agency also recommended engaging a qualified CGMP consultant to assess manufacturing systems and evaluate the effectiveness of corrective actions.
Failure to adequately resolve the violations could result in additional regulatory measures, including seizure, injunction, or restrictions affecting product approvals.
FDA
7. What Pharmaceutical Manufacturers Can Learn From FDA Warning Letter 320-26-112
The findings provide important lessons for pharmaceutical companies, biotechnology laboratories, and organizations responsible for maintaining FDA-regulated manufacturing operations.
Regulatory compliance requires more than written standard operating procedures. Manufacturers must demonstrate that procedures are consistently followed, equipment performs reliably, laboratory methods are scientifically sound, and quality systems can identify and correct problems.
Regular internal audits, independent laboratory assessments, equipment calibration, and comprehensive validation programs can help organizations identify weaknesses before they escalate into regulatory violations.
Pharmaceutical companies should also maintain robust documentation practices, conduct meaningful root cause investigations, and verify that corrective actions remain effective over time.
Investing in preventive maintenance, laboratory equipment qualification, and employee training can help reduce operational disruptions while supporting regulatory readiness.
8. The Importance of Pharmaceutical Laboratory Support and CGMP Compliance
FDA Warning Letter 320-26-112 illustrates how failures across multiple pharmaceutical quality systems can create substantial regulatory and operational risks.
From aseptic manufacturing and particulate inspection to stability testing and laboratory equipment qualification, each component contributes to overall pharmaceutical product quality.
Professional pharmaceutical laboratory support services can assist manufacturers with equipment calibration, preventive maintenance, analytical instrument qualification, IQ/OQ/PQ documentation, and laboratory compliance preparation.
However, external service providers do not replace a manufacturer's responsibility to maintain effective CGMP systems and independent quality oversight.
For pharmaceutical manufacturers seeking to strengthen laboratory operations, proactive equipment management and scientifically justified validation practices are essential.
Conclusion: FDA Compliance Requires Continuous Quality Oversight
The FDA's August 2026 warning letter to K.C. Pharmaceuticals demonstrates the serious consequences of inadequate manufacturing controls, deficient laboratory testing, and ineffective quality management.
The findings underscore the importance of maintaining validated processes, reliable laboratory equipment, accurate stability data, and comprehensive contamination prevention programs.
For pharmaceutical manufacturers throughout the United States, the central lesson is clear: CGMP compliance must be maintained continuously, supported by documented evidence, effective quality oversight, and ongoing operational improvements.
Official source: FDA Warning Letter 320-26-112 — K.C. Pharmaceuticals, Inc., August 12, 2026
About GL Technologies
GL Technologies, based in San Diego, is a specialized service provider catering to the highly regulated industries of biopharmaceuticals, pharmaceuticals, medical devices, and government sectors. The company focuses on delivering expert solutions in equipment calibration, validation, and compliance services, ensuring that clients meet stringent GMP (Good Manufacturing Practice) and FDA regulations. GL technologies is a trusted partner from commissioning new plants to decommissioning with compliance. GL can place dedicated motivated quality personnel on site anywhere. A program can be designed or revamped for the customers needs from design of CMMS to SOP development, specification development and performance of calibrations.
With a dedicated team of 29 technicians, GL Technologies offers precision calibration, preventative maintenance, and qualification services for laboratory and production equipment used in critical manufacturing and research processes. The company’s expertise is supporting its clients in maintaining regulatory compliance and operational efficiency.
As a full-service company specializing in equipment calibration, repair, and certification services for biopharmaceutical, pharmaceutical, and medical device industries. Our team has extensive experience working with sPRT calibrations along with CMMS software, HPLC OQ validation, and fume hood certifications. Companies of all sizes rely on our team to implement, maintain, and keep their research and manufacturing processes compliant with regulatory standards. Other specialties include building maintenance systems, and mass spectrometry calibrations. GL Tec specializes in IQ OQ PQ services for clients throughout San Diego, San Francisco, Los Angeles, Orange County, and Riverside!